Trial Profile
Multicenter assessment of transdermal therapy in overactive bladder with oxybutynin TDS (MATRIX).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2013
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms MATRIX
- 22 Sep 2011 Actual end date (May 2005) added as reported by ClinicalTrials.gov.
- 10 Apr 2007 Status change
- 10 Apr 2007 Status changed from in progress